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In vitro investigation of potential anti-diabetic activity 
of the corm extract of Hypoxis argentea Harv. Ex Baker
The corms of Hypoxis argentea are widely used as a traditio-
nal remedy for diabetes mellitus in South Africa. In this 
study, we investigated the effects of non-toxic concentrations 
(12.5–100 µg mL–1) of the aqueous extract of H. argentea (HAA) 
corms on glucose uptake, pancreatic beta cell prolife ra tion, and 
adipocyte differentiation. HAA stimulated glucose uptake in 
HepG2 cells up to 19.6 % and 17.0 % in L6 myotubes. Live-cell 
imaging microscopy revealed significant increases (p < 0.001) 
in total INS-1 cell numbers exposed to HAA, although no 
effect was observed on adipogenesis in 3T3-L1 pre-adipocytes. 
HAA produced weak to moderate inhibition of porcine pan-
creatic α-amylase, α-glucosidase, porcine pancreatic lipase, 
dipeptidyl peptidase IV (DPP IV) activities, as well as protein 
glycation. Our results suggest that the acclaimed anti-diabe tic 
effects of H. argentea could be mediated by its promotion of 
glucose utilization and preservation of pancreatic beta cell 
populations while preventing fat accumulation in adipocytes.
Keywords: Hypoxis argentea, diabetes, HepG2, INS-1, 3T3-L1, 
L6 myotubes, glucose uptake, adipogenesis
Diabetes mellitus is currently considered the third most significant chronic, non-com-
municable disease, responsible for most deaths and disabilities in the world (1), after can-
cer and cardiovascular diseases. With worldwide prevalence predicted to rise to double 
figures in 2035, due to increasing levels of modernized, sedentary lifestyles, diabetes mel-
litus has now emerged as a global public health challenge (2, 3). The huge financial burden 
of managing diabetes as a chronic health problem using conventional anti-diabetic medi-
cation, as well as the propensity for development of adverse effects have led to the explora-
tion of alternative anti-diabetic therapy using herbs and other plant-related remedies. 
However, many of these traditional remedies are yet to be scientifically validated with 
respect to their anti-diabetic efficacy.
Plants are generally known to be rich in compounds including phenolics, flavonoids, 
and terpenoids, which are reported to possess hypoglycemic properties (4, 5). In effect, ef-
fective management of diabetes mellitus in many parts of the world can benefit immensely 
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from the use of plant products, since they offer valuable sources of agents for long-term 
glycemic control with fewer side effects (6, 7). In Africa, several plants are used traditionally 
for anti-diabetic management, although many of them are yet to be scientifically validated.
Hypoxis argentea Harv. ex. Baker (Hypoxidaceae) is a perennial herb with leaves en-
closed in a sheath arising directly from an underground adventitious rootstock (corm), in 
what appears to be a false stem, while a slender stalk from the middle of the leaves bears 
an inflorescence of bright yellow, often star-shaped flowers. The corms are traditionally 
used in the Eastern Cape province of South Africa for the management of diabetes mellitus 
and other ailments. H. argentea corms are dark brown in color externally and white inter-
nally. When sliced, the corms exude a greyish resinous juice. The corms are reportedly 
crushed and soaked in cold water and administered orally to diabetic patients (8).
Previous investigations involving other Hypoxis species have identified a norlignan 
glyco side called hypoxoside, or chemically [(E)-1,5-bis(4′-β-d-glucopyranosyloxy-3′-hydro-
xy phenyl)pent-4-en-1-yne] as the most important and common phytochemical constituent 
(9, 10). Hypoxoside, as well as its hydrolytic product, rooperol, are believed to contribute 
to the anti-diabetic activities reported for some Hypoxis species (11). However, no reports 
of any study investigating the anti-diabetic properties of H. argentea were found in the 
literature. Recent investigations relating to anti-diabetic therapy development have ex-
plored approaches that involve the preservation and/or expansion of insulin-secreting, 
pancreatic β cell mass, either by stimulating increased β cell proliferation and/or decreas-
ing β cell apoptosis (12). These efforts are based on the understanding that β cell mass 
declines considerably in diabetic patients. In the present study, we sought to investigate 
the anti-diabetic potential of an aqueous extract of the Hypoxis argentea corms using different 
relevant cell-based bioassays in rat insulinoma (INS-1) cells, rat skeletal muscle (L6 
 myotubes), human hepatocellular carcinoma (HepG2) cells and murine pre-adipocytes 
(3T3-L1). The effects of the extract on enzymes relevant to intestinal carbohydrate and fat 
digestion, as well as non-enzymatic protein glycation, were also investigated.
EXPERIMENTAL
Plant material and preparation of plant extract
Whole plant samples, including the underground corms of H. argentea, were collected 
from localities within Alice district and Grahamstown, Eastern Cape, South Africa. Spe-
cifically, the plant can be found at the following coordinates: 33° 14.699’S 26° 35.653’E, along 
Botha’s Ridge, Grahamstown, South Africa. Plant materials were authenticated at the Sel-
mar Schonland Herbarium, Rhodes University, South Africa, and the Giffen Herbarium, 
University of Fort Hare, South Africa, where voucher specimens are kept.
The corms were initially separated from the rest of the plant and washed with clean 
tap water, after which they were sliced and oven dried at 30 °C. They were then milled into 
a coarse powder. About 200 g of ground plant material was soaked in distilled water (1 
litre) for about 24 hours. Due to the slimy nature of the mixture, it was initially filtered 
through a thick layer of sterile cotton wool before a repeat filtration using Whatmann No. 
1 filter paper. The resulting filtrate was frozen at –40 °C in an acetone chilling machine and 
later dried in a freeze-dryer. The aqueous extract was chosen for these studies as the corms 
are reportedly soaked in water for their traditional medicinal use. The extraction solvent 
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and processes were selected to resemble, as much as possible, the approach of ethno-me-
dicinal use by local healers in the Eastern Cape.
All spectrophotometric measurements were performed using a BioTek® PowerWave 
XS microplate reader (BioTek Instruments Inc., USA).
High performance-liquid chromatography coupled with time-of-flight mass spectrometry 
analysis (HPLC-TOF-MS/MS)
A high performance Agilent 1260 Infinity liquid chromatography (HPLC) system 
combined with an AB SCIEX 5600 Triple TOF hybrid mass spectrometer (MS) (Applied 
Biosystems Sciex, USA) equipped with an electrospray ionization source in negative mode 
was used to acquire mass spectra of the H. argentea aqueous extract. The LC system con-
sisted of a 4.6 × 50 mm reverse phase column (PoroShell 120, EC-C18, diameter 7 µm, Agi-
lent Technologies, USA). The mobile phase for gradient elution consisted of two solvents: 
solvent A: water with 0.1 % formic acid and solvent B: acetonitrile with 0.1 % formic acid. 
The elution gradient used was as follows: 75 % of solvent A for 0–8 min, followed by 25 % 
of solvent A for 8–15 min, and then 2 min with 75 % solvent A, giving a total run time of 
17 minutes. The injection volume was 5.0 µL and the flow rate was 1 mL min–1.
TOF-MS parameters were as follows: the declustering potential (DP) was 60 V, while 
collision energy (CE) was 35 V. Product ion parameters were as follows: ion spray voltage 
floating (ISVF): 4500; ion source gas 1 (GS 1): 31.026 kPa, ion source gas 2 (GS 2): 31.026 kPa 
and temperature (TEM): 450 °C. TOF masses were acquired using the Analyst Software for 
masses ranging from 100–1000 Da, while spectra were recorded in the ESI negative mode 
between m/z 50 and 1000.
Data were analyzed by ACD/Spectrus Processor 2017.2 software (Advanced Chemis-
try Development, Inc. Ontario, Canada). Putative identification of the major metabolites 
(peaks) in the extract was carried out using the RIKEN plant-specific MS/MS spectral da-
tabase (ReSpect) (RIKEN, Japan).
Routine maintenance of cell cultures
HepG2 cells (human liver cancer cell line) were purchased from Highveld Biological, 
(Johannesburg, South Africa). INS-1 cells were a gift from Prof. Guy Ritter (University of 
Bristol, UK). L6 cells were obtained from the Japanese Collection of Research Bioresources 
(JCRB) Cell Bank (Osaka, Japan). HepG2 and INS-1 cell lines were maintained routinely in 
fresh culture medium consisting of EMEM and RPMI-1640, containing 25 mmol L–1 HEPES, 
2 mmol L–1 glutamine supplemented with 10 % fetal bovine serum (FBS). L6 myotubes and 
3T3-L1 pre-adipocytes were cultured in Dulbecco’s modified Eagle ś medium (DMEM, 
Highveld Biological, Johannesburg, South Africa), with 10 % fetal bovine serum. Culture 
media were changed every 2–3 days. All cell cultures were incubated at 37 °C in a hu-
midified atmosphere with 5 % CO2.
INS-1 cell proliferation assay
The proliferative effect of H. argentea aqueous extract was studied in two assays on 
INS-1 cells, the crystal violet assay and live cell fluorescence imaging.
Crystal violet assay. – This assay was carried out according to the method of Feoktistova 
et al. (13), with slight modifications. INS-1 cells were seeded at a density of 8,000 cells per 
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well in 96-well micro-titer plates with 100 µL of complete medium. The extract was re-sus-
pended in DMSO (0.25 %, V/V) and added to the wells already containing complete medium 
to reach concentrations of 12.5, 25 and 50 µg mL–1. The plates were incubated for about 48 
hours at 37 °C in a humidified incubator and 5 % CO2. GABA (100 µmol L–1) was used as the 
positive control, while DMSO (0.25 %, V/V) served as the vehicle (untreated) control. Briefly, 
for the crystal violet assay, the treatments together with spent culture medium were re-
moved by aspiration and were replaced with 100 µL of formaldehyde in PBS (10 %, V/V) to 
fix the cells. After about 1 hour, the fix solution was removed and 100 µL crystal violet solu-
tion, 0.1 %, m/V (0.1 g of crystal violet dissolved in 100 mL distilled water and filtered 
through Whatman No. 1 filter paper) was added to each well, followed by incubation of the 
plates at room temperature for about 30 min. Excess dye was removed by washing the plates 
with distilled water while the plates were dried by tapping on a paper towel. The dye taken 
up by the cells was extracted with 10 % acetic acid (100 µL per well). The absorbance of the 
wells was read at 595 nm. Cell viability was expressed as a percentage.  
Live-cell fluorescence imaging of INS-1 cells
INS-1 cells were treated in culture in the same way as for the Crystal violet assay. 
Stock solution of nucleic acid stain, Hoechst 33342® [2 -́(4-ethoxyphenyl)-5-(4-methyl-1-
piperazinyl)-2,5 -́bi-1H-benzimidazole trihydrochloride trihydrate, Thermo Fisher Scien-
tific Inc., USA] of 10 mg mL–1 was prepared in distilled water.
The stock solution was further diluted 1:2,000 in PBS. All medium was removed from 
the cultured cells and replaced with 100 µL of Hoechst solution. The plates were incu bat ed 
for about 20 min at room temperature away from light using an aluminum foil paper. 
Propidium iodide (PI) (50 µg mL–1) was then added shortly before acquiring the im-
ages. Image acquisition was performed with an ImageXpress Micro XLS® microscope 
(Molecular Devices®, USA) using blue and red filters with a 40X objective. Nine fields were 
acquired per well and cells were scored by defined dimensions and analyzed by the 
MetaXpress® software.
Glucose uptake assay in HepG2 cells
Glucose utilization assays were performed with simple modifications of the methods 
used by Deutschlander et al. (14). HepG2 cells were initially dislodged by brief exposure 
to 0.25 % trypsin in phosphate-buffered saline, then seeded in new growth medium in 
96-well culture plates at a density of 6,000 cells per well in 200 µL of growth medium per 
well. The cells were allowed to adhere and grow in a humidified incubator (5 % CO2 at 37 
°C) for three days. Two cell-free rows were included to serve as blanks for the glucose 
utilization assay. On day 3, without changing the medium, 10 µL-aliquots of the plant 
extract (prepared at final concentrations of 25 and 100 µg mL–1) and the positive controls, 
metformin (1 µmol L–1) and berberine (50 µmol L–1) were added to each well (six repli-
cates for respective wells). The cells were incubated for further 48 hours. At the end of 
incubation, all spent medium was removed and then replaced with 25 µL of incubation 
buffer (RPMI 1640 diluted with PBS containing 0.1 % BSA) containing 8 mmol L–1 glucose. 
The plates were then incubated for a further 3 h at 37 °C. Ten µL of the incubation me-
dium from each well was transferred to a new 96-well plate, and the glucose concen-
tration in the medium was determined by adding 200 µL of glucose oxidase reagent 
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(SERA-PAK Plus, Bayer, Germany) and developed for 15 min at 37 °C. Absorbance was 
measured at 510 nm. Thereafter, glucose utilization was calculated as the difference be-
tween the cell-free and cell-containing wells. Glucose utilization was expressed as per-
centage of the untreated controls.
Glucose uptake assay in L6 myotubes
L6 myoblasts were seeded into flat-bottom 96-well plates at a density of 3,000 cells per 
well, maintained in DMEM supplemented with 10 % fetal bovine serum and incubated 
in a 5 % CO2 humidified atmosphere at 37 °C. They were allowed to adhere and grow 
to about 90 % confluence, after which the culture medium was replaced with DMEM 
containing 2 % horse serum. The culture was then left for an additional five days to allow 
differentiation into myotubes. Two cell-free rows were included to serve as blanks for the 
glucose utilization assay. Forty-eight hours prior to the glucose utilization assay, the cul-
ture medium was replaced and an aliquot (10 µL) of each plant extract (prepared at final 
concentrations of 12.5, 25 and 50 µg mL–1) was added using five replicates for each treat-
ment. The cells were incubated in the presence of the extracts or insulin (positive control, 
1 µmol L–1) for a further 48 h. The spent medium was removed and replaced with 25 µL 
incubation buffer containing 8 mmol L–1 glucose (RPMI 1640 medium diluted with PBS 
containing 0.1 % BSA) and this was incubated for 3 h at 3 °C. An aliquot of 10 µL of the 
medium from each well was transferred into a new 96-well plate and the glucose concen-
tration was determined as described for HepG2 cells.
MTT cytotoxicity assay
For each of the glucose uptake assays in HepG2 and L6 cells, toxicity assays were 
conducted on the cells, after determination of glucose concentration, to determine the 
proportion of cells that actually participated in glucose uptake. To achieve this goal, 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 0.5 mg mL–1 in RPMI-
1640) was added to the appropriate wells of each plate, which were then incubated at 37 °C 
for 3 h. MTT is a yellow tetrazolium dye that is reduced by live cells to a purple formazan, 
the absorbance of which is directly proportional to cell density. At the end of incubation, 
the medium was aspirated and 200 µL of DMSO was added to solubilize the formazan 
crystals formed in the cells. The absorbance of the wells was read at 540 nm.
3T3-L1 pre-adipocyte differentiation assay
The ability of the plant extract to induce differentiation and triglyceride accumulation 
was studied in 3T3-L1 pre-adipocytes according to the method of Ramirez-Zacarias et al. 
(15) with slight modifications. The cells were seeded into 48-well culture plates at a den-
sity of 6,000 cells per well and allowed to grow to 100 % confluence. Differentiation 
was induced in two-day post-confluent cells by treatment with plant extracts (prepared 
at 12.5, 25 and 50 µg mL–1) or the positive control (rosiglitazone, 1 µmol L–1) for 48 h. The 
cells were then cultured for an additional 8 days in normal culture medium (DMEM sup-
plemented with 10 % FBS) and the medium was replaced every 2–3 days.
On the tenth day, the spent culture medium was removed and the cells were 
washed gently with PBS. The cells were fixed by adding 500 µL of 10 % formaldehyde in 
394
A. Akinrinde et al.: In vitro investigation of potential anti-diabetic activity of the corm extract of Hypoxis argentea Harv. Ex Baker, Acta 
Pharm. 68 (2018) 389–407.
 
PBS per well. Fixing was allowed for 1 hour at room temperature. The fix solution was 
then aspirated and the cells were stained by adding 200 µL of pre-warmed Oil Red O 
(prepared initially as a stock solution of 0.5 % m/V in isopropanol). A working solution 
was prepared by adding 4 mL of distilled water to 6 mL of the stock solution. Staining 
was allowed for 15 min at 37 °C. The plates were then washed extensively with water to 
remove excess dye, followed by gentle drying in an oven at 37 °C. Triglyceride accumula-
tion was quantified by extracting the Oil red O stain with isopropanol (250 µL per well), 
after which 200 µL was transferred to a new 96-well plate) and the absorbance was mea-
sured at 520 nm. Excess isopropanol was removed, the plates were washed with water 
and dried at 37 °C and were then stained with Crystal Violet as previously described to 
normalize cell density.
α-Amylase inhibition
The plant extract was prepared at concentrations of 50, 100 and 200 µg mL–1 in phos-
phate buffer (pH 6.8). Five µL of enzyme solution (10 mg porcine pancreatic amylase 
solubilized in 100 mL phosphate buffer) was pipetted into the appropriate well of a 96-well 
plate. Thereafter, 15 µL of test samples (plant extract), positive control (acarbose, 100 µmol 
L–1) or phosphate buffer were added to the enzyme in respective wells. Control wells with-
out enzyme and without the substrate (starch) were also included. The plate was pre-incu-
bated for 15 minutes at 37 °C to allow interaction of the enzyme with different compounds. 
The reaction was started by the addition of 20 µL starch solution to the wells, and the plate 
was again incubated for 30 min at 37 °C. The reaction was terminated by adding 10 µL 
of 1 mol L–1 HCl to each well, followed by 75 µL of an iodine reagent. Absorbance was 
measured at 580 nm.
α-Glucosidase inhibition
The ability of the plant extract to inhibit α-glucosidase activity was measured using 
the chromogenic method (16) with slight modifications. It measures the rate of release of 
p-nitrophenol (PNP) from p-nitrophenyl-α-d-glucopyranoside (PNP-GLUC), which serves 
as substrate for the enzyme. The released PNP gives a yellow color, the absorbance of 
which can be measured spectrophotometrically. The reaction mixture within wells of a 
96-well micro-titer plate consisted of 5 µL of plant extract (prepared at concentrations of 
50, 100 and 200 µg mL–1) or the positive control, epigallocatechin gallate (EGCG, 10 µg 
mL–1) and 20 µL of α-glucosidase solution (α-glucosidase type 1 from Baker’s yeast was 
prepared at a concentration of 0.58 µg µL–1). This was pre-incubated at 37 °C for 5 min and 
the initial background absorbance was read at 405 nm. Ten µL of PNP-GLUC was 
then added and the reaction mixture was incubated again for 20 min at 37 °C. The reac-
tion was terminated by the addition of 25 µL of sodium carbonate solution (100 mmol L–1). 
The absorbance was measured again at 405 nm. Controls without enzyme and without the 
substrate (PNP-GLUC) were also included in the assay.
Protein glycation inhibition
The formation of fluorescent advanced glycation end-products when the protein, gel-
atin, was glycated with glyceraldehyde, was measured in this assay. Gelatin solution (50 
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µL) was first pipetted into the wells of a 96-well plate. Then, 40 µL of the positive control, 
aminoguanidine (20 mmol L–1) or the plant extracts (at 50 and 100 µg mL–1), was added to 
the respective wells. Thereafter, 10 µL of 500 mmol L–1 glyceraldehyde solution was added 
to each well. The plates were sealed and incubated at 37 °C for 24 hours. The fluorescent 
intensity was measured at an excitation wavelength of 370 nm and emission wavelength 
of 440 nm using a Biotek® Synergy MX fluorimeter (BioTek Instruments Inc., USA). The 
experiment was conducted in quadruplicates and fluorescence quench controls were 
also included for each sample.
Lipase inhibition assay
In this assay, the conversion of the substrate, p-nitrophenol phosphate (pNPP), was 
used to study lipase inhibition. Briefly, 10 µL of the extract (prepared at concentrations of 
50, 100 and 200 µg mL–1), positive control (Orlistat, 100 µmol L–1) and DMSO (vehicle) was 
pipetted into the respective wells of a 96-well plate. Freshly prepared porcine pancreatic 
lipase was added at four times the volume of the test samples, positive and negative con-
trols (40 µL). The plates were initially incubated at 37 °C for 15 min. Thereafter, 170 µL of 
the substrate solution was added to the wells. The substrate solution was a mixture of two 
solutions including solution A containing 1 mg mL–1 pNPP in 10 % isopropanol, while 
solution B consisted of 20 mg gum arabic, 40 mg sodium deoxycholate and 100 µL of Triton 
X-100, all dissolved in 18 mL of Tris-HCl buffer (pH 8.0). The plate was then incubated at 
37 °C for 25 min and the absorbance was read at 405 nm.
Dipeptidyl peptidase IV (DPP IV) inhibition
The method described by Al-Masri et al. (17), with slight modifications, was used in 
determining DPP IV inhibition. The chromogenic substrate Gly-Pro-p-nitroanilide (GPPN) 
was cleaved by DPP IV to release p-nitroanilide (pNA), a yellow colored product which can 
be measured colorimetrically. Briefly, 35 µL of extracts (prepared at 50 and 100 µg mL–1) 
and the positive control (Diprotin A, 50 µg mL–1) were initially mixed with 15 µL of the 
DPP IV enzyme solution in the respective wells of a 96-well plate. The assay included a 
no-sample blank in which the samples were replaced with buffer and a no-enzyme blank 
in which the enzyme solution was also replaced by the buffer. The plate was pre-incubated 
at 37 °C for 5 minutes to allow interactions of extracts and the enzyme, after which a back-
ground absorbance was measured. Thereafter, 50 µL of the substrate solution (Gly-Pro-pNA) 
was added to all wells and the plate was incubated at 37 °C for 30 min. The reaction was 
terminated by the addition of 25 µL of 25 % acetic acid. Absorbance was measured at 410 nm.
Data analysis
Six or eight replicates were performed for the cell-based assays, while four replicates 
were used for the enzymatic assays. Values for each treatment were compared with the 
untreated controls and, where required, the respective positive controls.
Statistical analysis was carried out using Graph Pad Prism software Version 5.01 and 
the test of significance was done using Student’s t-test (two-tailed). Differences between 
means were considered statistically significant at p values between 0.01 and 0.05.
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In this study, the in vitro assays of the effects of the aqueous extract of H. argentea 
(HAA) on mouse insulinoma (INS-1) cell numbers indicated that the extract showed some 
potential to stimulate proliferation of pancreatic beta cells. With Hoechst 33342® staining, 
HAA, at all the different concentrations of 12.5, 25 and 50 µg mL–1 produced a significant 
increase (p < 0.01) in the number of live INS-1 cells, up to 112.6, 115.5 and 113.1 %, resp., 
relative to the untreated control (100 %) (Fig. 1). This effect was similar to that obtained 
with the positive control, GABA, which produced cell viability up to 116.2 %. At the same 
time, propidium iodide staining revealed marginal decreases (p < 0.05), compared to the 
untreated controls, in the percentage of dead cells when INS-1 cells were exposed to HAA, 
producing cell deaths of only 0.47, 0.41 and 0.36 % at 12.5, 25 and 50 µg mL–1, resp., while 
Fig. 1. Proliferative effects of the Hypoxis argentea aqueous extract in pancreatic β cells using ImageX-
press micro XLS analysis: a) Hoechst (blue) and propidium iodide (red) staining of INS-1 cells follow-
ing 48 h exposure to the aqueous extract of Hypoxis argentea (50 µg mL–1) and the positive control 
(GABA, 100 µmol L–1). Blue staining indicates live cells, red staining indicates dead cells, b) percent-
age of live and dead INS-1 cells achieved by MultiWave scoring. Values are expressed as percentage 
of control (mean ± SD, n = 8). *Significant increase at p < 0.01 for live cells or p < 0.05 for dead cells, 
compared to the control.
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control wells had 0.70 % cell death. Crystal Violet staining of INS-1 cells in a separate assay 
merely revealed a tendency for HAA to maintain cell populations at near control values, 
producing 99.7, 98.8 and 97.8 % cell viability at the respective concentrations of 12.5, 25 and 
50 µg mL–1 (Fig. 2). There were no significant differences between cell viability in cells 
exposed to the different extract concentrations compared to that of cells exposed to GABA. 
The results obtained from both assays have, however, shown clearly that HAA was not 
toxic to INS-1 cells at the concentrations tested.
From the results described above, the potential of H. argentea to stimulate proliferation 
of INS-1 cells was well demonstrated by image cytometry. The stimulation of β cell prolife-
ration by herbal extracts was proposed to occur by means of direct interactions of the 
constituents of these extracts with the cells (18). Natural products such as genistein were 
shown to induce β cell proliferation and insulin secretion by activation of protein kinase 
A and the extracellular signal-regulated kinase (19). Other flavonoids such as quercetin 
and catechin are believed to maintain the integrity of β cells via their effects in diminishing 
oxidative stress in β cells (20, 21).
Stimulation of glucose uptake
H. argentea demonstrated promising anti-hyperglycemic potential in HepG2 and L6 
cell lines, effects that were largely concentration-dependent. It is believed that plant ex-
tracts that promote glucose utilization in skeletal muscle, as obtained in this study, act by 
mechanisms that mimic insulin-mediated signaling, possibly involving increased mobili-
zation of GLUT 4 molecules to the plasma membrane (22).
The results obtained for the in vitro assay of glucose uptake in HepG2 cells in the pres-
ence of HAA are represented in Fig. 3a. The results indicate that HAA showed some po-
tential in lowering blood glucose levels, producing a concentration-dependent increase in 
glucose uptake at 25 µg mL–1 (103.9 %) and 100 µg mL–1 (119.6 %) relative to the untreated 
control (100 %). The observed increase in glucose uptake by HAA was statistically signifi-
Fig. 2. Crystal violet assay of aqueous extracts of Hypoxis argentea on INS-1 cells (expressed as % of the 
control ± SD, n = 8).
GABA – gamma-amino butyric acid, HAA – Hypoxis argentea aqueous extract, UT – untreated control
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cant (p < 0.05) at the higher concentration (100 µg mL–1) compared to the untreated control. 
Metformin (1 µmol L–1) and berberine (50 µmol L–1), used as positive controls, produced 
increases in glucose uptake up to 169.7 and 115.1 %, resp. HAA produced a significantly 
lower (p < 0.01) amount of glucose uptake compared to metformin. However, the extract 
exhibited a similar degree of glucose uptake compared to berberine. The observed in-
creases in glucose uptake obtained with the different compounds may be relevant, since 
the toxicity assay conducted on the cells revealed that neither HAA nor positive controls 
were toxic to HepG2 cells (Fig. 3b).
Fig. 4a depicts glucose uptake when L6 myotubes were exposed to HAA at different 
concentrations. The extract again showed a potential to stimulate glucose uptake in L6 myo-
tubes, producing 111.3, 116.3 and 117.0 % glucose uptake, resp., at 12.5, 25 and 50 µg mL–1. 
This effect was statistically significant (p < 0.05) at all extract concentrations compared to the 
Fig. 3. a) Glucose uptake in HepG2 cells (expressed as % of the control ± SD, n = 6) when exposed to 
the aqueous extract of Hypoxis argentea (HAA) corms, b) toxicity (expressed as % of the control ± SD, 
n = 6) of the plant extract to HepG2 cells used in the glucose uptake assay. * Significant difference (p 
< 0.05) compared to the untreated control.
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untreated control. The positive control, insulin (1 µmol L–1), however, produced slightly better 
stimulation, up to 123.3 % glucose uptake, compared to the untreated control. When com-
pared with the extract, however, this difference was not statistically significant. Again, HAA 
showed no potential for toxicity to L6 myotubes at the concentrations tested (Fig. 4b), sug-
gesting that the observed stimulation of glucose uptake by HAA might be a true reflection 
of its hypoglycemic potential.
Stimulation of glucose uptake obtained in this study with H. argentea is supported by 
previous studies on H. hemerocallidea, a prominent member of the Hypoxis genus (23). The 
plant was found to exert a hypoglycemic effect in rats, probably due to its content of phy-
tosterols and/or sterolins. The present study, however, is the first attempt to investigate the 
mechanisms of anti-diabetic actions of H. argentea in in vitro assays. Our observations of 
increased glucose uptake in HepG2 cells and L6 myotubes could be considered relevant, 
since the extract did not exhibit any potential toxicity to these cells at the concentrations 
tested, which were considered to be physiologically relevant from previous studies (24).
Fig. 4. a) Glucose uptake in L6 myotubes (expressed as % of the control ± SD, n = 6) when exposed to 
the aqueous extract of Hypoxis argentea corms, b) toxicity (expressed as % of the control ± SD, n = 6) of 
the plant extract to L6 myotubes used in the glucose uptake assay. * Significant difference (p < 0.05) 
compared to the untreated control.
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Triglyceride accumulation
Elevated levels of triglycerides in peripheral tissues can produce lipotoxicity and also 
contribute to obesity-related type 2 diabetes mellitus. Fig. 5 shows the effect of HAA on 
triglyceride accumulation in 3T3-L1 pre-adipocytes, as revealed by Oil Red O staining. 
HAA did not produce any significant alteration in adipocyte differentiation at three con-
centrations, 12.5, 25 and 50 µg mL–1, when compared to the untreated control. However, 
Oil Red O staining in pre-adipocytes treated with the positive control, rosiglitazone, 
showed intense reddish staining, indicating the presence of large amounts of cytoplasmic 
lipid droplets in the differentiated adipocytes. Spectrophotometric quantification of the 
amount of stain taken up by the cells indicated slight changes in triglyceride accumulation 
with values of 100.1, 100.2 and 100.4 % at 12.5, 25 and 50 µg mL–1 of HAA, resp. Rosigli-
tazone, on the other hand, produced a significant increase (p < 0.05) in triglyceride accu-
mulation of up to 144.6 %. Rosiglitazone thus produced a significant increase (p < 0.05) in 
triglyceride accumulation compared either to the extract or the untreated controls.
Drugs such as rosiglitazone are known to induce adipogenesis in pre-adipocytes by 
increasing the transcription of adipocyte-specific genes required for the formation of tri-
Fig. 5. Effect of the aqueous extract of the Hypoxis argentea corms on 3T3-L1 pre-adipocyte differen-
tiation: a) plates show the appearance of Oil Red O stained cells after 10 days of treatment with the 
plant extract (12.5 and 50 µg mL–1) or rosiglitazone (1 µmol L–1), b) quantitation of the effect of the 
Hypoxis argentea aqueous extract on 3T3-L1 pre-adipocyte triglyceride accumulation. Values are ex-
pressed as mean ± SD of four replicates corrected for cell density. * Significant difference (p < 0.05) 
compared to the untreated control.
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glyceride droplets (25). During differentiation, the level of triglycerides increases in adipo-
cytes via mechanisms involving up-regulation of the CCAAT/enhancer-binding proteins 
(C/EBP α, β and γ) and the peroxisome proliferator-activated receptor gamma (PPARγ) 
(26). The results of this study show that H. argentea exerts no pro-adipogenic effects at the 
concentrations tested, since its addition to 3T3-L1 pre-adipocytes did not alter significant-
ly the triglyceride accumulation in these cells.
Certain anti-diabetic drugs are able to mobilize triglycerides from ectopic tissues 
(such as liver and muscle) into the adipose tissue. This process is beneficial in such ectopic 
tissues as it prevents the development of insulin resistance, although there is the risk of 
excessive triglyceride accumulation in adipose tissue, which may result in adipose hyper-
trophy and might, in turn, pose a risk for the development of type 2 diabetes (27). Thus, 
recent studies have argued that the ideal anti-diabetic agent is one that neither blocks nor 
induces adipogenesis and/or triglyceride accumulation (28).
Inhibition of carbohydrate and lipid-digesting enzymes and protein glycation
Mechanisms of anti-diabetic action by some compounds may involve the inhibition 
of carbohydrate-digesting enzymes, including α-amylase and α-glucosidase, as well as 
processes that lead to the development of diabetic complications (e.g., protein glycation). 
Table I summarizes the results of the inhibitory activities of HAA against α-amylase, 
α-glucosidase, lipase, dipeptidyl peptidase IV (DPP IV) and glycation of gelatin. Alpha-
amylase and alpha-glucosidase are the key carbohydrate-digesting small intestinal en-
zymes, which have been recognized as therapeutic targets for modulating post-prandial 
hyperglycemia. The percentage inhibitory activity of HAA against α-glucosidase at 50, 100 
and 200 µg mL–1 was 16.3, 19.0 and 31.5 %, resp., compared to the untreated control. These 
values may be physiologically relevant as higher concentrations of the extract will be pres-
ent in the gut. EGCG, a known inhibitor of α-glucosidase activity, produced as much as 
57.5 % inhibition. However, the extract did not exhibit any appreciable inhibition of 
α-amylase activity at any of the three concentrations, while acarbose, used as positive 
control, produced as much as 94.7 % inhibition of α-amylase activity.
Protein glycation, a non-enzymatic glycosylation reaction between reducing sugars 
and free amino groups of proteins, is one of the consequences of increased levels of glucose 
in the blood of diabetic patients. HAA produced very weak inhibition (5.5 %) of gelatin 
glycation at the highest concentration tested (100 µg mL–1). This was in contrast to amino-
guanidine, which exhibited as much as 65.7 % inhibition. The enzyme lipase plays a key 
role in fat digestion by hydrolyzing dietary triglycerides to monoglycerides and free fatty 
acids. Free fatty acids are known to contribute to the development of insulin resistance in 
type 2 diabetes (29). In this study, HAA showed weak inhibitory activities against porcine 
pancreatic lipase (Table I). At 50, 100 and 200 µg mL–1, the extract produced only 3.2, 5.4 
and 5.4 % inhibition of lipase activity, resp., all of which were much lower compared to 58.8 
% obtained with Orlistat, which was used as a positive control. DPP IV normally degrades 
incretin hormones such as GLP-1, which are known to enhance β-cell function. Inhibition 
of DPP IV leads to increased half-life and circulating levels of incretins. As indicated in 
Table I, DPP IV inhibition was virtually non-existent for the plant extract at the concentra-
tions tested compared to Diprotin A, the positive control, which exhibited 75.8 % inhibi-
tion of DPP IV activity.
402
A. Akinrinde et al.: In vitro investigation of potential anti-diabetic activity of the corm extract of Hypoxis argentea Harv. Ex Baker, Acta 
Pharm. 68 (2018) 389–407.
 
Compounds in H. argentea extract and their possible impact
Compound identification of the Hypoxis argentea aqueous extract was carried out by 
HPLC-TOF-MS/MS. The negative ionization mode was preferred, since it has been reported 
to be more sensitive for the detection of polyphenols and also has lower limits of detection 
compared to the positive mode of analysis (30).
Eight major peaks were identified or tentatively identified according to their retention 
times and fragment ions in the specific plant natural product database, as shown in Fig. 6 
Table I. Inhibitory effects of Hypoxis argentea on the activities of the key intestinal carbohydrate and fat 
digesting enzymes and protein glycation
                                                                                 Inhibition (%)
α-Amylase
Acarbose 94.7 ± 0.0
HAA (50 µg mL–1) NI
HAA (100 µg mL–1) NI
HAA (200 µg mL–1) NI
α-Glucosidase
EGCG 57.5 ± 4.8
HAA (50 µg mL–1) 16.30 ± 4.8*
HAA (100 µg mL–1) 19.00 ± 6.5*
HAA (200 µg mL–1) 31.5 ± 4.0*
Lipase
Orlistat 58.8 ± 0.3
HAA (50 µg mL–1) 3.2 ± 2.4*
HAA (100 µg mL–1) 5.4 ± 1.1*
HAA (200 µg mL–1) 5.4 ± 0.7*
DPP IV
Diprotin A 75.8 ± 0.3
HAA (50 µg mL–1) NI
HAA (100 µg mL–1) NI
Protein glycation
Aminoguanidine 71.0 ± 5.0
HAA (50 µg mL–1) 13.0 ± 1.0*
HAA (100 µg mL–1) 12.0 ± 2.0*
EGCG – epigallocatechin gallate, HAA – Hypoxis argentea aqueous extract, NI – no inhibition 
Values are expressed as mean ± SD, n = 4.
* Significantly lower (p < 0.05) compared to the positive control.
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and Table II. With regard to bioactivity against diabetes mellitus, compounds at peaks 1, 
5 and 8 were deemed relevant. Peak 1 was characterized as epicatechin, displaying the 
parent ion with m/z 288.936 at 2.523 minutes. Epicatechin is a natural flavonoid found at 
high concentrations in green tea and known to be important in the management of diabe-
tes (31). Peak 5 was tentatively characterized as quinic acid, with MS/MS spectra giving 
m/z 191.020 at 4.265 minutes. Quinic acid has been reported to act synergistically with 
quercetin to alleviate degenerative changes in the liver, kidney and pancreatic tissues in 
streptozotocin-induced diabetic rats (32). Peak 8 was tentatively identified as a coumarin 
derivative, 7-hydroxy-4-methyl coumarin, which displayed the deprotonated ion [M-H]– at 
m/z 174.955. The anti-diabetic activity of coumarin derivatives such as cloricromene has 
been reported (33).
Table II. Mass data of major compounds detected in the aqueous extract of the Hypoxis argentea corms










1 (+)-Epicatechin C15H14O6 2.523 [M-H]– 290.079 288.936
158.978, 174.956, 187.097, 
272.960, 276.936, 288.936, 
304.915, 402.918, 418.894
2 l-β-homotrypto-phan HCl C12H14N2O2 2.723 [M-H]
– 218.25 216.909
111.948, 216.909, 260.873, 
276.846, 358.839, 396.797, 
418.779
3 Glycyl-l-proline C7H12N2O3 3.053 [M-H]– 172.18 171.030
165.041, 171.030, 189.041, 
195.050, 223.045, 267.071, 
327.092, 385.135
4 Glycyl-l-proline C7H12N2O3 3.798 [M-H]– 172.18 171.030
109.029, 171.030, 172.033, 
187.097, 191.020, 339.031, 
365.049, 513.145
5 d-(-)-quinic acid C7H12O6 4.265 [M-H]– 192.17 191.020
111.009, 129.019, 187.097, 
191.020, 192.023, 405.028, 
406.029, 421.002
6 Dihydrocapsaicin C18H29NO3 6.428 [M-H]– 307.43 169.015
169.015, 170.017, 187.097, 
324.073, 325.076, 341.109, 
387.115, 477.173
7 Esculin sesquihy-drate C15H16O9 13.888 [M-H]
– 340.079 325.183
265.149, 305.214, 311.167, 
325.183, 339.201, 357.206, 
409.236, 794.951
8 7-Hydroxy-4- methyl coumarin C10H8O3 14.750 [M-H]
– 176.17 174.955
174.955, 341.108, 357.208, 
397.275, 459.346, 535.384, 
614.499, 729.403
404
A. Akinrinde et al.: In vitro investigation of potential anti-diabetic activity of the corm extract of Hypoxis argentea Harv. Ex Baker, Acta 
Pharm. 68 (2018) 389–407.
 
Fig. 6. Total ion chromatogram of the Hypoxis argentea aqueous extract analyzed by high performance 
liquid chromatography coupled with triple time-of-flight mass spectrometry.
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CONCLUSIONS
Tentative identification of compounds on the basis of accurate mass spectrometric 
measurements in the Hypoxis argentea entea extract by LC-TOF-MS has revealed the pres-
ence of phytochemicals with reported anti-diabetic properties and suggests that the plant 
warrants further exploration as a potential source of antidiabetic agents. Future detailed 
analyses utilizing retention time and/or mass spectral data of reference standards are, 
however, required for the confirmation of their actual identities.
Overall, our results support the traditional medicinal use of H. argentea in diabetes 
mellitus, with its probable mechanisms of action including stimulation of glucose uptake 
via insulin-dependent pathways in skeletal muscle and/or insulin-independent pathways 
in hepatocytes, as well as the probable stimulation of pancreatic β cell proliferation. We 
recommend further studies in in vivo environments to confirm the promising anti-diabetic 
potential observed in the in vitro cell-based bio-assays.
Acronyms, abbreviations, symbols. – AMPK – adenosine monophosphate protein kinase, BSA – 
bovine serum albumin, C/EBP – CCAAT/enhancer-binding proteins, DMEM – Dulbecco’s modified 
Eagle’s medium, DMSO – dimethyl sulfoxide, DPP IV – dipeptidyl peptidase IV, EGCG – epigallocat-
echin gallate, EMEM – Eagle’s modified essential medium, FBS – fetal bovine serum, GABA – gamma 
amino butyric acid, GLP-1 – glucagon-like peptide 1, GLUT – glucose transporter, GPPN – Gly-Pro-
para-nitroanilide, HAA – Hypoxis argentea aqueous extract, HepG2 – human hepatocellular carcinoma 
cell line, HPLC-TOF-MS/MS – high performance-liquid chromatography coupled with time-of-flight 
mass spectrometry, INS-1 – insulinoma cell line, MTT – 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet-
razolium bromide, PBS – phosphate-buffered saline, PI3-K – phosphatidyl inositol 3-kinase, PKB – 
protein kinase B, PNP-GLUC – p-nitrophenyl-α-d-glucopyranoside, pNPP – p-nitrophenol phosphate, 
PPARγ – peroxisome proliferator-activated receptor gamma, RPMI – Roswell Park Memorial Insti-
tute.
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